<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928485</url>
  </required_header>
  <id_info>
    <org_study_id>CASE6812</org_study_id>
    <secondary_id>NCI-2013-01372</secondary_id>
    <secondary_id>P30CA043703</secondary_id>
    <nct_id>NCT01928485</nct_id>
  </id_info>
  <brief_title>Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer</brief_title>
  <official_title>Randomized Study of Sunphenon Decaffeinated Capsules in Men With Low-Risk Prostate Cancer on Active Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanjay Gupta PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well green tea extract works in treating patients
      with low-risk prostate cancer. Green tea extract contains ingredients that may prevent or
      slow the growth of certain cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess changes in the levels of total- and free- prostate-specific antigen (PSA), free
      to total PSA (f/tPSA) ratio and insulin-like growth factor 1 (IGF-I) levels and IGF-I/free
      PSA (fPSA) ratio, insulin-like growth factor binding protein 3 (IGFBP-3), and vascular
      endothelial growth factor (VEGF) after Sunphenon 90DCF-T (green tea extract) supplementation
      during the period between recruitment and biopsy.

      SECONDARY OBJECTIVES:

      I. To evaluate the effects of oral ingestion on Sunphenon 90DCF-T supplementation during the
      period between recruitment and biopsy in the reactivation of glutathione S-transferase pi 1
      (GSTP1) (whole blood deoxyribonucleic acid [DNA]); levels of antigen identified by monoclonal
      antibody Ki-67 (Ki-67), cluster of differentiation 34 (CD34), and M30 apopotosense in the
      prostate tissue.

      II. To evaluate the effects of oral ingestion of Sunphenon 90DCF-T during the period between
      recruitment and biopsy on histologic findings in prostate tissue such as nuclear measurements
      viz. shape, size and texture and quality of life (QOL) assessment.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM A: Patients undergo active surveillance for 52 weeks.

      ARM B: Patients receive green tea extract orally (PO) once daily (QD) for 52 weeks in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Accrual
  </why_stopped>
  <start_date type="Actual">August 30, 2013</start_date>
  <completion_date type="Actual">November 7, 2016</completion_date>
  <primary_completion_date type="Actual">October 5, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the Levels of Total-PSA (tPSA)</measure>
    <time_frame>From baseline at 52 weeks</time_frame>
    <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the f/tPSA Ratio</measure>
    <time_frame>From baseline at 52 weeks</time_frame>
    <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in IGF-I Levels</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
    <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the IGF-I/fPSA Ratio</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
    <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the Level of IGFBP-3</measure>
    <time_frame>Baseline to 52 weeks</time_frame>
    <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the Level of VEGF</measure>
    <time_frame>Baseline up to 52 weeks</time_frame>
    <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the Levels of Free-PSA (f-PSA)</measure>
    <time_frame>from baseline at 52 weeks</time_frame>
    <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of Oral Ingestion of Green Tea Extract in the Reactivation of GSTP1 (Whole Blood DNA)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures analysis of variance (ANOVA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Oral Ingestion of Green Tea Extract on Levels of Ki-67</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures ANOVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Oral Ingestion of Green Tea Extract on Levels of CD34</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures ANOVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Oral Ingestion of Green Tea Extract on Levels of M30 Apoptosense in the Prostate Tissue</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures ANOVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Oral Ingestion of Sunphenon 90 DCF-T on Histologic Findings in Prostate Tissue Such as Nuclear Measurements Viz. Shape, Size and Texture</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Effects of oral ingestion of Sunphenon 90 DCF-T on histologic findings in prostate tissue such as nuclear measurements viz. shape, size and texture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) Assessed by the Expanded Prostate Cancer Index Composite (EPIC-26)</measure>
    <time_frame>At 26 weeks</time_frame>
    <description>Quality of Life (QOL) assessed by the Expanded Prostate Cancer Index Composite (EPIC-26). Scores for each domain (urinary incontinence, bowel, sexual, hormonal) range from 0-100, with higher scores indicating better clinical assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) Assessed by the Expanded Prostate Cancer Index Composite (EPIC-26)</measure>
    <time_frame>at 52 weeks</time_frame>
    <description>Quality of Life (QOL) assessed by the Expanded Prostate Cancer Index Composite (EPIC-26). Scores for each domain (urinary incontinence, bowel, sexual, hormonal) range from 0-100, with higher scores indicating better clinical assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) Assessed by Medical Outcomes Study 12-item Short Form Health Survey (SF-12)</measure>
    <time_frame>At 26 weeks</time_frame>
    <description>Quality of Life (QOL) assessed by SF-12. The questionnaire consists of 12 items questioned weighted and summed to provide physical and mental health scores (PCS and MCS). The two composite scores are computed using the scores on twelve questions that range from 0 to 100, with higher score indicating better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) Assessed by Medical Outcomes Study 12-item Short Form Health Survey (SF-12)</measure>
    <time_frame>At 52 weeks</time_frame>
    <description>Quality of Life (QOL) assessed by SF-12. Quality of Life (QOL) assessed by SF-12. The questionnaire consists of 12 items questioned weighted and summed to provide physical and mental health scores (PCS and MCS). The two composite scores are computed using the scores on twelve questions that range from 0 to 100, with higher score indicating better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Health Inventory in Men Score (SHIM Score)</measure>
    <time_frame>At 26 weeks</time_frame>
    <description>SHIM score - The SHIM score measures the severity of the participant's Erectile Dysfunction (ED) in points on a scale as follows:
22 - 25: No significant erectile dysfunction 17 - 21: Mild erectile dysfunction 12 - 16: Mild-to-moderate erectile dysfunction 8 - 11: Moderate erectile dysfunction 5 - 7: Severe erectile dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Health Inventory in Men Score (SHIM Score)</measure>
    <time_frame>At 52 weks</time_frame>
    <description>SHIM score - The SHIM score measures the severity of the participant's Erectile Dysfunction (ED) in points on a scale as follows:
22 - 25: No significant erectile dysfunction 17 - 21: Mild erectile dysfunction 12 - 16: Mild-to-moderate erectile dysfunction 8 - 11: Moderate erectile dysfunction 5 - 7: Severe erectile dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Symptoms as Assessed by American Urological Association Symptom Index (AUA)</measure>
    <time_frame>At 26 weeks</time_frame>
    <description>Urinary symptoms as assessed by American Urological Association Symptom Index (AUA). This is a 7-item symptom index measures frequency, nocturia, weakness of stream, hesitancy, intermittence, incomplete emptying and urgency. Scores range between 0 to 35, with higher scores indicating a worse clinical assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Symptoms as Assessed by American Urological Association Symptom Index (AUA).</measure>
    <time_frame>At 52 weeks</time_frame>
    <description>Urinary symptoms as assessed by AUA score. This is a 7-item symptom index measures frequency, nocturia, weakness of stream, hesitancy, intermittence, incomplete emptying and urgency. Scores range between 0 to 35, with higher scores indicating a worse clinical assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Stage I Prostate Cancer</condition>
  <condition>Stage IIA Prostate Cancer</condition>
  <condition>Stage IIB Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (active surveillance)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo active surveillance for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Sunphenon)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>active surveillance</intervention_name>
    <description>Undergo active surveillance</description>
    <arm_group_label>Arm A (active surveillance)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunphenon</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm B (Sunphenon)</arm_group_label>
    <other_name>Green tea polyphenols</other_name>
    <other_name>Green tea extract</other_name>
    <other_name>Sunphenon 90DCD-T</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (active surveillance)</arm_group_label>
    <arm_group_label>Arm B (Sunphenon)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A (active surveillance)</arm_group_label>
    <arm_group_label>Arm B (Sunphenon)</arm_group_label>
    <other_name>The Expanded Prostate Cancer Index Composite (EPIC-26)</other_name>
    <other_name>American Urological Association (AUA) symptom index</other_name>
    <other_name>Quality of Life (SF-12)</other_name>
    <other_name>Food Questionnaire</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be males with histologically confirmed and clinically localized
             low-grade and low-volume prostate cancer demonstrated at the time of initial diagnosis

          -  Prostate biopsy must be positive for cancer: clinically localized T1c or T2a, PSA ≤
             10, Gleason ≤ 6 at the time of initial diagnosis. As the intent of serial biopsy is to
             ensure that the disease has not progressed to the stage or grade of requiring
             treatment, the presence of a negative biopsy following an initial positive biopsy
             (coupled with clinically localized T1c or T2a PSA ≤10 and Gleason ≤6 for a patient who
             has had no treatment, will not render the patient ineligible. If the consecutive
             biopsy is either negative, or if positive and remains clinically localized T1c or T2a,
             PSA≤10 and Gleason ≤6, the patient is eligible

          -  Willing to refrain from the concurrent use of high-dose (200 mg or higher per day) of
             vitamins, antioxidants, Proscar, Advodart, and anti-inflammatory agents

          -  Willing to sign an Institutional Review Board (IRB)-approved informed consent document
             and adhere to the protocol

          -  Willing and able to take oral medications

          -  Willing to refrain from drinking any kind of tea (including herbal tea) or using
             supplements containing green tea for the duration of the study

          -  Subjects must have newly diagnosed (within 1 year), previously untreated prostate
             cancer without other malignancy; therefore, no prior therapies are permitted

          -  Total bilirubin within normal institutional limits

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) ≤
             institutional upper limit of normal

          -  Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤
             institutional upper limit of normal

          -  Serum creatinine within normal institutional limits

          -  Subject must be willing to limit alcohol to moderate use which is defined as: up to
             one drink a day for women or two drinks a day for men; examples of one drink include:

               -  Beer: 12 fluid ounces (355 milliliters)

               -  Wine: 5 fluid ounces (148 milliliters)

               -  Distilled spirits (80 proof): 1.5 fluid ounces (44 milliliters)

        Exclusion Criteria:

          -  Patients who are receiving any other investigational agents

          -  Patients with known concurrent malignancy

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Sunphenon 90 DCF-T or other agents used in this study

          -  Recent consumption of tea (six or more cups per day) or use of supplements containing
             green tea within one week of randomization; or concomitant use of at least 400 mg per
             day of a nonsteroidal anti-inflammatory (NSAID) agent two or more times per week

          -  Patients with uncontrolled intercurrent illness including, but not limited to ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Patients who have received prior hormonal or surgical therapy for prostate cancer;
             including prior brachytherapy or radiation therapy

          -  Signs or symptoms of progressive or uncontrolled liver disease

          -  Known malignancy at any site within the last two years; with the exception of basal
             cell carcinoma (BCC)

          -  Participation in a research trial within the past three months

          -  Any condition that would interfere with the ability to give informed consent or comply
             with the study protocol

          -  Hypersensitivity to tea products or any of the inactive ingredients found in the drug
             product capsules

          -  Patients with a known history of Gilbert's syndrome
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Ponsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 21, 2013</study_first_submitted>
  <study_first_submitted_qc>August 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2013</study_first_posted>
  <results_first_submitted>February 17, 2020</results_first_submitted>
  <results_first_submitted_qc>February 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2020</results_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Case Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Sanjay Gupta PhD</investigator_full_name>
    <investigator_title>Co-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A (Active Surveillance)</title>
          <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
        </group>
        <group group_id="P2">
          <title>Arm B (Sunphenon)</title>
          <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A (Active Surveillance)</title>
          <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
        </group>
        <group group_id="B2">
          <title>Arm B (Sunphenon)</title>
          <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Levels of Total-PSA (tPSA)</title>
        <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
        <time_frame>From baseline at 52 weeks</time_frame>
        <population>Participants with available PSA values</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Active Surveillance)</title>
            <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sunphenon)</title>
            <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Levels of Total-PSA (tPSA)</title>
          <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
          <population>Participants with available PSA values</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="2.29"/>
                    <measurement group_id="O2" value="5.1" spread="NA">no standard deviation due to only 1 observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in the f/tPSA Ratio</title>
        <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
        <time_frame>From baseline at 52 weeks</time_frame>
        <population>Participants with available PSA values</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Active Surveillance)</title>
            <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sunphenon)</title>
            <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the f/tPSA Ratio</title>
          <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
          <population>Participants with available PSA values</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.07"/>
                    <measurement group_id="O2" value="0.16" spread="NA">no standard deviation due to only 1 observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in IGF-I Levels</title>
        <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
        <time_frame>Baseline to 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Active Surveillance)</title>
            <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sunphenon)</title>
            <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in IGF-I Levels</title>
          <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" spread="0.1"/>
                    <measurement group_id="O2" value="2.12" spread="NA">no standard deviation due to only 1 observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in the IGF-I/fPSA Ratio</title>
        <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
        <time_frame>Baseline up to 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Active Surveillance)</title>
            <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sunphenon)</title>
            <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the IGF-I/fPSA Ratio</title>
          <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="0.77"/>
                    <measurement group_id="O2" value="3.02" spread="NA">no standard deviation due to only 1 observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Level of IGFBP-3</title>
        <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
        <time_frame>Baseline to 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Active Surveillance)</title>
            <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sunphenon)</title>
            <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Level of IGFBP-3</title>
          <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.93"/>
                    <measurement group_id="O2" value="5.54" spread="NA">no standard deviation due to only 1 observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Level of VEGF</title>
        <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
        <time_frame>Baseline up to 52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Active Surveillance)</title>
            <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sunphenon)</title>
            <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Level of VEGF</title>
          <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" spread="20.6"/>
                    <measurement group_id="O2" value="0" spread="NA">no standard deviation due to only 1 observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Levels of Free-PSA (f-PSA)</title>
        <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
        <time_frame>from baseline at 52 weeks</time_frame>
        <population>Participants with available PSA values</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Active Surveillance)</title>
            <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sunphenon)</title>
            <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Levels of Free-PSA (f-PSA)</title>
          <description>The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated.</description>
          <population>Participants with available PSA values</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.17"/>
                    <measurement group_id="O2" value="0.7" spread="NA">no standard deviation due to only 1 observation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Oral Ingestion of Green Tea Extract in the Reactivation of GSTP1 (Whole Blood DNA)</title>
        <description>The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures analysis of variance (ANOVA).</description>
        <time_frame>Up to 52 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Oral Ingestion of Green Tea Extract on Levels of Ki-67</title>
        <description>The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures ANOVA.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>ROI staining scores could not be determined because no positive stained cells in post-biopsy specimens. Tissue from 3 participants in Arm A and 1 participant from Arm B was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Active Surveillance)</title>
            <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sunphenon)</title>
            <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Oral Ingestion of Green Tea Extract on Levels of Ki-67</title>
          <description>The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures ANOVA.</description>
          <population>ROI staining scores could not be determined because no positive stained cells in post-biopsy specimens. Tissue from 3 participants in Arm A and 1 participant from Arm B was analysed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Oral Ingestion of Green Tea Extract on Levels of CD34</title>
        <description>The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures ANOVA.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>ROI staining scores could not be determined because no positive stained cells in post-biopsy specimens. Tissue from 3 participants in Arm A and 1 participant from Arm B was analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Active Surveillance)</title>
            <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sunphenon)</title>
            <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Oral Ingestion of Green Tea Extract on Levels of CD34</title>
          <description>The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures ANOVA.</description>
          <population>ROI staining scores could not be determined because no positive stained cells in post-biopsy specimens. Tissue from 3 participants in Arm A and 1 participant from Arm B was analysed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Oral Ingestion of Green Tea Extract on Levels of M30 Apoptosense in the Prostate Tissue</title>
        <description>The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures ANOVA.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>M30 levels could not be determined because there were no tumor cells in biopsy</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Active Surveillance)</title>
            <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sunphenon)</title>
            <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Oral Ingestion of Green Tea Extract on Levels of M30 Apoptosense in the Prostate Tissue</title>
          <description>The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures ANOVA.</description>
          <population>M30 levels could not be determined because there were no tumor cells in biopsy</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Oral Ingestion of Sunphenon 90 DCF-T on Histologic Findings in Prostate Tissue Such as Nuclear Measurements Viz. Shape, Size and Texture</title>
        <description>Effects of oral ingestion of Sunphenon 90 DCF-T on histologic findings in prostate tissue such as nuclear measurements viz. shape, size and texture</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>Could not be determined because there were no tumor cells in biopsy</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Active Surveillance)</title>
            <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Sunphenon)</title>
            <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Oral Ingestion of Sunphenon 90 DCF-T on Histologic Findings in Prostate Tissue Such as Nuclear Measurements Viz. Shape, Size and Texture</title>
          <description>Effects of oral ingestion of Sunphenon 90 DCF-T on histologic findings in prostate tissue such as nuclear measurements viz. shape, size and texture</description>
          <population>Could not be determined because there were no tumor cells in biopsy</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QOL) Assessed by the Expanded Prostate Cancer Index Composite (EPIC-26)</title>
        <description>Quality of Life (QOL) assessed by the Expanded Prostate Cancer Index Composite (EPIC-26). Scores for each domain (urinary incontinence, bowel, sexual, hormonal) range from 0-100, with higher scores indicating better clinical assessment.</description>
        <time_frame>At 26 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QOL) Assessed by the Expanded Prostate Cancer Index Composite (EPIC-26)</title>
        <description>Quality of Life (QOL) assessed by the Expanded Prostate Cancer Index Composite (EPIC-26). Scores for each domain (urinary incontinence, bowel, sexual, hormonal) range from 0-100, with higher scores indicating better clinical assessment.</description>
        <time_frame>at 52 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QOL) Assessed by Medical Outcomes Study 12-item Short Form Health Survey (SF-12)</title>
        <description>Quality of Life (QOL) assessed by SF-12. The questionnaire consists of 12 items questioned weighted and summed to provide physical and mental health scores (PCS and MCS). The two composite scores are computed using the scores on twelve questions that range from 0 to 100, with higher score indicating better health.</description>
        <time_frame>At 26 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QOL) Assessed by Medical Outcomes Study 12-item Short Form Health Survey (SF-12)</title>
        <description>Quality of Life (QOL) assessed by SF-12. Quality of Life (QOL) assessed by SF-12. The questionnaire consists of 12 items questioned weighted and summed to provide physical and mental health scores (PCS and MCS). The two composite scores are computed using the scores on twelve questions that range from 0 to 100, with higher score indicating better health.</description>
        <time_frame>At 52 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexual Health Inventory in Men Score (SHIM Score)</title>
        <description>SHIM score - The SHIM score measures the severity of the participant's Erectile Dysfunction (ED) in points on a scale as follows:
22 - 25: No significant erectile dysfunction 17 - 21: Mild erectile dysfunction 12 - 16: Mild-to-moderate erectile dysfunction 8 - 11: Moderate erectile dysfunction 5 - 7: Severe erectile dysfunction</description>
        <time_frame>At 26 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexual Health Inventory in Men Score (SHIM Score)</title>
        <description>SHIM score - The SHIM score measures the severity of the participant's Erectile Dysfunction (ED) in points on a scale as follows:
22 - 25: No significant erectile dysfunction 17 - 21: Mild erectile dysfunction 12 - 16: Mild-to-moderate erectile dysfunction 8 - 11: Moderate erectile dysfunction 5 - 7: Severe erectile dysfunction</description>
        <time_frame>At 52 weks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Symptoms as Assessed by American Urological Association Symptom Index (AUA)</title>
        <description>Urinary symptoms as assessed by American Urological Association Symptom Index (AUA). This is a 7-item symptom index measures frequency, nocturia, weakness of stream, hesitancy, intermittence, incomplete emptying and urgency. Scores range between 0 to 35, with higher scores indicating a worse clinical assessment.</description>
        <time_frame>At 26 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Symptoms as Assessed by American Urological Association Symptom Index (AUA).</title>
        <description>Urinary symptoms as assessed by AUA score. This is a 7-item symptom index measures frequency, nocturia, weakness of stream, hesitancy, intermittence, incomplete emptying and urgency. Scores range between 0 to 35, with higher scores indicating a worse clinical assessment.</description>
        <time_frame>At 52 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A (Active Surveillance)</title>
          <description>Patients undergo active surveillance for 52 weeks.
active surveillance: Undergo active surveillance
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
        </group>
        <group group_id="E2">
          <title>Arm B (Sunphenon)</title>
          <description>Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
Sunphenon: Given PO
laboratory biomarker analysis: Correlative studies
Questionnaire Administration: Ancillary studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lee Ponsky</name_or_title>
      <organization>Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</organization>
      <phone>+1 216-844-4831</phone>
      <email>lee.ponsky@uhhospitals.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

